Research Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)

Posted by Geri Gentry on Jun 15th, 2026

Several analysts have recently updated their ratings and price targets for Revolution Medicines (NASDAQ: RVMD):

6/2/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada from $165.00 to $182.00. They now have an “outperform” rating on the stock.
6/1/2026 – Revolution Medicines had its price target raised by HC Wainwright from $169.00 to $195.00. They now have a “buy” rating on the stock.
6/1/2026 – Revolution Medicines had its “outperform” rating reaffirmed by Wedbush.
6/1/2026 – Revolution Medicines had its price target raised by Oppenheimer Holdings, Inc. from $165.00 to $195.00. They now have an “outperform” rating on the stock.
5/21/2026 – Revolution Medicines is now covered by Sanford C. Bernstein. They set a “market perform” rating and a $151.00 price target on the stock.
5/21/2026 – Revolution Medicines was upgraded by Sanford C. Bernstein to “hold”.
5/18/2026 – Revolution Medicines is now covered by Truist Financial Corporation. They set a “buy” rating and a $179.00 price target on the stock.
5/7/2026 – Revolution Medicines had its price target raised by Guggenheim to $205.00. They now have a “buy” rating on the stock.
5/7/2026 – Revolution Medicines had its price target raised by Royal Bank Of Canada to $165.00. They now have an “outperform” rating on the stock.
5/7/2026 – Revolution Medicines had its price target raised by Wedbush to $165.00. They now have an “outperform” rating on the stock.
5/7/2026 – Revolution Medicines had its price target raised by Piper Sandler to $172.00. They now have an “overweight” rating on the stock.
4/27/2026 – Revolution Medicines was upgraded by Truist Financial Corporation to “strong-buy”.
4/22/2026 – Revolution Medicines had its “buy” rating reaffirmed by HC Wainwright.
4/21/2026 – Revolution Medicines had its “sell (d-)” rating reaffirmed by Weiss Ratings.
4/20/2026 – Revolution Medicines had its “buy” rating reaffirmed by Stifel Nicolaus.

Insiders Place Their Bets

In related news, insider Mark A. Goldsmith sold 120,000 shares of Revolution Medicines stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $150.09, for a total value of $18,010,800.00. Following the completion of the transaction, the insider directly owned 276,698 shares in the company, valued at approximately $41,529,602.82. This trade represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Jack Anders sold 2,753 shares of Revolution Medicines stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total value of $273,868.44. Following the completion of the transaction, the chief financial officer owned 125,512 shares of the company’s stock, valued at $12,485,933.76. This trade represents a 2.15% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 148,592 shares of company stock valued at $20,855,132. 7.60% of the stock is owned by company insiders.

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Research Analysts’ Weekly Ratings Changes for Revolution Medicines (RVMD)

Insiders Place Their Bets

Recommended Stories

You might be interested in: